ライフサイエンスコーパス: blocking antibody

1 O] mice or mice treated with a pan-IFN-alpha-blocking antibody).

2 nt, similar to the effect of a CD47 function-blocking antibody.

3 treatment enhanced the efficacy of anti-PD-1 blocking antibody.

4 nuated with Cx43(E2), a specific hemichannel-blocking antibody.

5 This effect was mitigated by NKG2D-blocking antibody.

6 erum from each patient with or without Ang-2-blocking antibody.

7 t in UPAR positive cells blocked with a UPAR-blocking antibody.

8 atidylinositol-3 kinase inhibitor and by MET-blocking antibody.

9 IGF-1, growth hormone, and an IGF-1 receptor-blocking antibody.

10 PV-specific T-cell assays in the presence of blocking antibody.

11 alanine completely abolished binding of the blocking antibody.

12 ein of P. falciparum can induce transmission-blocking antibody.

13 elease was inhibited by a specific anti-CCR4 blocking antibody.

14 ented by an anti-HCV envelope glycoprotein 2-blocking antibody.

15 by the JNK inhibitor or an anti-DCC function-blocking antibody.

16 eletion of the HA-binding LINK domain, or HA-blocking antibody.

17 , and this inhibition is reduced by the CS-E blocking antibody.

18 ented by preincubation with a beta1-integrin blocking antibody.

19 Fos signaling was suppressed with a function-blocking antibody.

20 TRPC1/4/5 channel blocker and T1E3, a TRPC1 blocking antibody.

21 g a Janus kinase (JAK) inhibitor and an IL-7-blocking antibody.

22 ct was abolished by treatment with anti-TLR2 blocking antibody.

23 mplement C3(-/-) mice and by injection of C5-blocking antibody.

24 in a manner that was abrogated by anti-PD-L1 blocking antibody.

25 complex with two distinct antagonists and a blocking antibody.

26 elopment efforts focusing on antagonists and blocking antibodies.

27 axis, partially inhibited by antihuman CXCR3 blocking antibodies.

28 , and functional activity was assessed using blocking antibodies.

29 their ability to induce malaria transmission-blocking antibodies.

30 resence or absence of anti-TLR2 or anti-TLR4 blocking antibodies.

31 oaded HDL, S1P receptor antagonists, and S1P-blocking antibodies.

32 ot receive vemurafenib nor immune checkpoint-blocking antibodies.

33 its natural IgA isotype were the most potent blocking antibodies.

34 f vaccines, which should avoid inducing such blocking antibodies.

35 enic NMO-IgG autoantibodies into therapeutic blocking antibodies.

36 attenuated by pretreatment with alphavbeta6-blocking antibodies.

37 ignal significantly decreased (P < 0.001) by blocking antibodies.

38 ins was probed using specific inhibitors and blocking antibodies.

39 the development of paralogue-specific ligand-blocking antibodies.

40 acity to induce functional allergen-specific blocking antibodies.

41 ageal cancer cells was inhibited by anti-NGF blocking antibodies.

42 V antibodies, which was reversed by FcgammaR blocking antibodies.

43 nd in mice in which MRC-1 is inhibited using blocking antibodies.

44 associated with allergen-neutralizing IgG(4)-blocking antibodies.

45 IFN-gamma signaling were disrupted by using blocking antibodies.

46 On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be

47 n was inhibited by an alphavbeta6/8 integrin blocking antibody (264RAD) and a small molecule inhibito

48 at this response can be inhibited by the Shh-blocking antibody 5E1 indicates that the Shh response in

49 pecific immunotherapy (AIT) induces specific blocking antibodies (Ab), which are claimed to prevent I

50 A LIF-blocking antibody abolished C26 CM-induced STAT reporter

51 Acute treatment of slices with function-blocking antibodies (Abs) against Nogo-A or against NgR1

52 cal development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discu

53 ibition were evaluated in vivo with anti-NGF blocking antibodies administered both in rat chronic hyp

54 IFN-gamma blocking antibody administered to Sphk2(-/-) mice or del

55 anti-VCAM-1 or intraperitoneal (i.p.) beta7 blocking antibody administration was used to determine t

56 globulin, IgA, and histo-blood group antigen-blocking antibodies against both vaccine GI.1 and GII.4c

57 f scavenger receptor class B, galectin-3, or blocking antibodies against CD36, suggesting that pyrral

58 Blocking antibodies against CD55 or virus envelope glyco

59 Blocking antibodies against cytotoxic T-lymphocyte-assoc

60 RETR, antagonized IL-2 and IL-15 better than blocking antibodies against IL-2Ralpha or IL-2Rbeta.

61 specific antieosinophil therapies, including blocking antibodies against IL-5, IL-13, IL-33, and thym

62 id during development, an event prevented by blocking antibodies against p75 neurotrophin receptor (p

63 Immunotherapy using checkpoint-blocking antibodies against PD-1 has produced impressive

64 observations in cancer clinical trials using blocking antibodies against PD-1 or CTLA4, or both, show

65 xidative burst in the presence or absence of blocking antibodies against PD1 or TIM3.

66 owth in neuronal cells that was inhibited by blocking antibodies against proNGF, indicating that pros

67 after peripheral administration, functional blocking antibodies against RANTES and eotaxin reduced t

68 Immunotherapy using checkpoint-blocking antibodies against targets such as CTLA-4 and P

69 Here we investigated whether function-blocking antibodies against the nerve-fiber growth inhib

70 In this work, we show that function-blocking antibodies against the nerve-fiber growth inhib

71 Moreover, administration of blocking antibodies against TM and EPCR significantly re

72 Blocking antibodies against Toll-like receptor (TLR)1/TL

73 signaling, as discovered by pretreatment of blocking antibodies against Toll-like receptors (TLRs) a

74 A blocking antibody against (ILFA1), disrupting the lympho

75 Elvax resin implants filled with either a blocking antibody against BDNF or the BDNF protein were

76 Finally, a blocking antibody against beta8 inhibited immunosuppress

77 fectivity, an effect blocked by a monoclonal blocking antibody against NRP1.

78 Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1

79 Some mice were given a blocking antibody against TLR2 or a TLR4 inhibitor.

80 This effect was not inhibited by LIF or IL6 blocking antibodies alone, but was prevented by dual IL6

81 agents not in widespread clinical use, CD47-blocking antibody (alphaCD47Ab), soluble complement rece

82 Using receptor-blocking antibodies and activation peptides, we determin

83 ling to unmask the binding sites for albumin blocking antibodies and albumin on the receptor, which r

84 s reduced to control cell levels by integrin-blocking antibodies and by inhibition of FAK.

85 The mechanisms were investigated using blocking antibodies and cells isolated from cytokine-def

86 soluble E2 with a lower affinity than other blocking antibodies and do not neutralize virus.

87 gated by septin immunodepletion and function-blocking antibodies and is induced by recombinant septin

88 Here we show that NRP1-blocking antibodies and NRP1 silencing can counteract li

89 Here, using blocking antibodies and pharmacological inhibitors, we d

90 n early after initiation of therapy with PD1-blocking antibodies and predicts a clinical response to

91 mimics the native trimer might elicit entry-blocking antibodies and prevent virus infection.

92 on, assays were performed in the presence of blocking antibodies and/or small-molecule inhibitors tar

93 ted mice were treated with an IL-10 receptor blocking antibody and a TLR-9 agonist, and parameters of

94 tivated receptor (PAR)-2 was evaluated using blocking antibody and dedicated lentiviral small hairpin

95 ectly targeted NET components with a histone blocking antibody and DNase1, both of which protected mi

96 on is also reduced in the presence of a CD44-blocking antibody and is associated with a specific incr

97 Using functional blocking antibody and RNAi, we further demonstrate that

98 production of IgG4 isotype allergen-specific blocking antibodies, and decreased allergic inflammatory

99 ys in vivo hypoallergenicity, induces potent blocking antibodies, and is captured by human DCs much m

100 ity, its capacity for eliciting transmission-blocking antibodies, and its apparent lack of immunizati

101 poptosis was attenuated by BAPTA, VIVIT, Fas blocking antibody, and a caspase-3/7 inhibitor.

102 a protective role in allergy by acting as a blocking antibody, and inhibiting mast cell degranulatio

103 To restore T-cell responses, blocking antibodies (anti-cytotoxic T-lymphocyte antigen

104 (a known CD206 ligand), free mannose, and a blocking antibody (anti-hMR).

105 We also show that a blocking antibody antigen-binding fragment binds to the

106 Interestingly, a systemic anti-Bst2 blocking antibody approach attenuated kidney fibrosis in

107 HBGA-blocking antibodies are a surrogate for neutralization i

108 Immune checkpoint-blocking antibodies are actively used to treat multiple

109 squamous cell carcinoma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatmen

110 Thus, ADCC-defective Fn14-blocking antibodies are not only possible novel GVL effe

111 ecause of the recent development of anti-NGF blocking antibodies as a possible new pain treatment, su

112 Nase L activation in BMM treated with IFNAR1-blocking antibody, as well as in Ifnar1(-/-) BMM, both e

113 nd safety of pembrolizumab, a humanized PD-1-blocking antibody, at a dose of 200 mg every 3 weeks in

114 eous CKD, therapeutic delivery of anti-TWEAK blocking antibodies attenuated disease progression, pres

115 In contrast to normal B7-H1 blocking antibody, B7-H1 antibodies capable of activatin

116 likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.

117 temic administration of anti-C5- or anti-C5a-blocking antibodies blunted the CNV-induced production o

118 nt also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure.

119 Checkpoint-blocking antibodies can generate potent anti-tumor respo

120 When isolated without the use of blocking antibodies, CD41+ HSCs possessed long-term repo

121 RAS(G13D) CRC patients benefit from the EGFR-blocking antibody cetuximab.

122 up, tumors following BRAFi, aPDL1, and CSF1R-blocking antibody combination therapy did not show great

123 rosine kinases, such as HER2, and developing blocking antibody-combination therapy with chemotherapie

124 n JAG2-deficient thymic lobes or with Notch3-blocking antibodies confirm the importance of Jagged2/No

125 and CD11b, and mechanistic experiments using blocking antibodies confirmed a functional role for CD31

126 a specific IgG4 response, and production of blocking antibodies correlated with TH2 response downreg

127 We hypothesized that nivolumab, a PD-1-blocking antibody, could inhibit tumor immune evasion in

128 eutic effect of the humanized anti-Jagged1/2-blocking antibody CTX014 on MDSC-mediated T-cell suppres

129 the other hand, a JAK inhibitor and an IL-7-blocking antibody decreased the invasiveness of PC-3 cel

130 human colonoid-derived IEC treated with CD47-blocking antibodies demonstrate impaired epithelial cell

131 MT1-MMP-blocking antibodies diminished migration, proliferation,

132 , differential and sequential treatment with blocking antibodies directed against PVR, DNAM-1, PECAM,

133 Incubation of platelets with a blocking antibody directed against CD36 or with a pharma

134 ceptor protected mice after treatment with a blocking antibody directed against PD-1.

135 Further, we show that VEGFR-2 and VEGFR-1 blocking antibodies displayed opposing effects on tumor

136 the therapeutic potential of using an IL-25 blocking antibody during a chronic inflammatory setting.

137 cgammaRIIB-transgenic (Tg) mice, FcgammaRIIB-blocking antibodies effectively deleted target cells in

138 oradiotherapy, and ex vivo culture with PD-1-blocking antibody enhanced HPV-specific T-cell responses

139 n of VE-cadherin clustering at AJs (function-blocking antibody, FBA) inhibited dilatation to acetylch

140 n clustering at adherens junctions (function-blocking antibody; FBA) reduced endothelial dilatation i

141 survival advantage with addition of a TIM-3 blocking antibody following failure of PD-1 blockade.

142 nd that a short course of anti-IL-7 receptor blocking antibody following T cell depletion, combined w

143 ns in trophoblasts were determined using two blocking antibodies for measuring migration and prolifer

144 ed into the development of IL-23- and IL-17A-blocking antibodies for the treatment of SpA.

145 ine loops of death receptor ligands, because blocking antibodies for TNFalpha, tumor necrosis factor-

146 tory role because of the noninflammatory and blocking antibody function of IgG4.

147 oglycans, as demonstrated by the use of CS-E blocking antibody GD3G7.

148 sis of tumor cells mediated by CD47-specific blocking antibodies has been proposed to be the major ef

149 s recognized by current therapeutic function-blocking antibodies has resulted in previously unanticip

150 tion of regulatory lymphocyte subsets and of blocking antibodies have been described.

151 B7-H1 (aka PD-L1) blocking antibodies have been used in treatment of human

152 lization, for example, angiopoietin-2 (Ang2)-blocking antibodies, have shown promising results in pre

153 te its ability to induce high-titer invasion-blocking antibodies in a controlled human challenge tria

154 Using gene deletion and function-blocking antibodies in mice, we determined that the lymp

155 Using both genetic mutants and blocking antibodies in mice, we show that retinoic acid

156 sion was as effective as anti-PD-1 and PD-L1-blocking antibodies in the control of B16 melanoma, or E

157 Administration has approved three checkpoint-blocking antibodies in three disease indications, and ad

158 he sensitivity of pancreatic tumors to PD-L1-blocking antibody in association with increased tumoral

159 Inhibition of IL-6 by its blocking antibody in BMM-OB cocultures diminishes the in

160 maturation pathway for a potent transmission-blocking antibody in humans.

161 Thus, SD3 binds Fy and elicits blocking antibodies, indicating that it contains residue

162 of breast cancer cells to cetuximab (an EGFR-blocking antibody)-induced inhibition of cell signaling

163 Here we found that an ANG2-blocking antibody inhibited embryonic lymphangiogenesis,

164 d depletion of NRP1, but not the use of NRP1-blocking antibodies, inhibited FGFR signaling and reduce

165 e with therapeutic intent-for example, using blocking antibodies inhibiting PD-1/PD-L1 (programmed de

166 While infusion of IL-10R blocking antibody, initiated at day 60, caused a signifi

167 Notably, injection of LIF-blocking antibody into PDAC-bearing mice reduced intratu

168 lerosis (MS) during treatment with the CTLA4-blocking antibody ipilimumab for metastatic melanoma.

169 he cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab results in durable response

170 ence with the Dll4 signal by ligand-specific blocking antibodies is sufficient to inhibit the endothe

171 IgG4 is a blocking antibody isotype with anti-inflammatory potenti

172 were attenuated by the Fcgamma receptor IIa-blocking antibody IV.3, suggesting they are mediated by

173 Injections of mouse neonates with BMP9/10 blocking antibodies lead to HHT-like vascular defects in

174 genesis that, when interrupted by PDGFRalpha-blocking antibody, led to decreased hepatoblast prolifer

175 Changes in sIgE levels and reduced IL-4 and blocking antibody levels could thus be used as indicator

176 es from baseline in cockroach IgE, IgG4, and blocking antibody levels.

177 The application of blocking antibodies may be an alternative treatment stra

178 glioblastoma (GBM) with bevacizumab, a VEGFA-blocking antibody, may accelerate tumor cell invasion an

179 0.47; P = .01), and treatment with the CD49d-blocking antibody natalizumab resulted in significantly

180 ogrammed cell death protein 1 (PD-1) pathway-blocking antibody nivolumab has shown substantial therap

181 n cancer therapy to a similar degree as PD-1 blocking antibodies, offering a next-generation approach

182 est the effect of an IL-21 receptor (IL-21R) blocking antibody on the early phase of allograft reject

183 with CD was reduced by EGF receptor and IL15 blocking antibodies only when used in combination.

184 Moreover, angiogenin antagonism by blocking antibodies or angiogenin inhibitor neomycin dec

185 ted intact Bp and the presence or absence of blocking antibodies or chemokines.

186 rimental ICV either in mice treated with VWF-blocking antibodies or in VWF(-/-) mice.

187 types can phagocytose PMPs, and by using TAM-blocking antibodies or siRNA knockdown of individual TAM

188 alpha3 but not alpha6 integrin subunit using blocking antibodies or small interfering RNA abrogated t

189 In a murine model, administration of CD47-blocking antibodies or targeted inactivation of the Cd47

190 uld be mitigated by addition of either a Fas blocking antibody or a caspase-3 inhibitor.

191 tion of endothelial activation with a VCAM-1 blocking antibody or a VAP-1 small molecule inhibitor le

192 g, either by injections of low dose of ICOSL blocking antibody or by halving the gene dose of Icos in

193 rasound, we demonstrated that beta1 integrin-blocking antibody or endothelial cell-specific depletion

194 Treatment with an IFN-beta receptor blocking antibody or knockdown of IFN-beta significantly

195 Further, by using a nectin-4 blocking antibody or recombinant MeV unable to enter cel

196 VDAC-1) or treatment with a VDAC-1 selective blocking antibody or silencing mRNA expression of the ch

197 However, the addition of neuropilin 1 (Nrp1)-blocking antibody or siRNA knockdown of Nrp1 inhibits Se

198 Notably, injection of beta1 integrin-blocking antibody or tamoxifen-induced endothelial cell-

199 ta-KO] mice or mice treated with an IFN-beta-blocking antibody) or IFN-alpha (IFN regulatory factor 7

200 Attenuation of RNLS by RNAi, blocking antibodies, or an RNLS-derived inhibitory pepti

201 depletion of anti-IgE reactivity from IVIG, blocking antibodies, or inhibitors, were used to investi

202 PD-1 inhibition on melanoma cells by RNAi, blocking antibodies, or mutagenesis of melanoma-PD-1 sig

203 HMGB1 depletion, HMGB1 blocking antibody, or TLR-4 inhibition attenuated senesc

204 inhibitor trametinib together with the PD-1-blocking antibody pembrolizumab (triplet; n = 60) or pla

205 nizing Siglec-8 in combination with integrin blocking antibodies, pharmacologic inhibitors, phosphopr

206 roconversion and a corresponding increase in blocking antibody potential was observed.

207 In vivo, we demonstrated that anti-NGF blocking antibodies prevent and reverse PH in rats throu

208 , endothelin receptor antagonists and/or KIT blocking antibodies prevent precocious melanocyte stem c

209 FcgammaRIIB-blocking antibodies prevented internalization of the CD2

210 Consequently, treatment with Notch1 or VCAM1-blocking antibodies prevented Notch-driven metastasis, a

211 While c-kit blocking antibodies prevented spreading, imatinib blocke

212 TWEAK/Fn14 deletion or TWEAK-blocking antibody prevented histamine/platelet-activatin

213 antly, therapeutic intervention by IFN-gamma blocking antibody prevented neuronal deafferentation and

214 In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients

215 lls, either with cyclosporine A or anti-CD1d blocking antibody, prolonged mice survival.

216 Furthermore, RGMa blocking antibodies promoted neuronal survival, and enha

217 We have generated blocking antibodies, raised in Eda-deficient mice, again

218 e of the NRG1/HER3 axis using clinical-grade blocking antibodies re-sensitizes tumors to hormone depr

219 Furthermore, targeting BMP4 with blocking antibody recovered the functionality of the vas

220 Administration of VCAM-1 and beta7-integrin blocking antibodies reduced IL-33-induced eosinophilic i

221 ermore, the application of GPVI- or integrin-blocking antibodies reduced the formation of platelet-as

222 model, depletion of macrophages with a CSF1R-blocking antibody reduced the efficacy of 5AZA-C + DFMO

223 Furthermore, exposure to a MFGE8-blocking antibody reduces phagocytic activity.

224 RATIONALE: Mepolizumab, an IL-5-blocking antibody, reduces exacerbations in patients wit

225 Therapeutic strategies using anti-PD-1-blocking antibodies reported unparalleled effectiveness

226 ects (P = .09) but no evidence of functional blocking antibody response.

227 LR2 knockout mice developed TLR2-independent blocking antibody responses with similar kinetics.

228 , as well as histoblood group antigen (HBGA) blocking antibody responses, were measured before and af

229 T, especially with regard to IgG4 levels and blocking antibody responses.

230 A CDH1 function-blocking antibody restores prostatic identity, bud outgr

231 ment of ovarian tumor-bearing mice with PD-1 blocking antibody resulted in an increase in IL10 levels

232 ng, by addition of cyclopamine or a function-blocking antibody, resulted in large, ectopic ganglia ad

233 ctive inhibition of EphB4 using a functional blocking antibody results in defective lymphatic valve d

234 Experiments with knockout mice and blocking antibodies reveal that the uropod elongation an

235 In loss-of-function studies, blocking antibodies revealed that lymphangiogenesis 14 d

236 ibition of Wnt5a by either RNAi knockdown or blocking antibody reversed Smarcd3/Baf60c-induced EMT.

237 An IL6-blocking antibody reversed the effects of PTPN2-deficien

238 Furthermore, administration of VEGFR blocking antibody selectively improved survival of Shh-d

239 Rats treated with RGMa blocking antibodies showed significantly improved recove

240 n cancer therapy to a similar degree as PD-1-blocking antibodies.Significance: These findings show ho

241 ment with paclitaxel and an anti-mouse PD-L1 blocking antibody significantly improved the therapeutic

242 Addition of anti-B7-H1 blocking antibody significantly reversed the inhibitory

243 Treatment with VEGF or VEGFR-2 blocking antibodies similarly reduced tumor angiogenesis

244 Administration of blocking antibodies specifically against CTGF domain 4 o

245 Function blocking antibody studies revealed haptokinetic spreadin

246 Cell transfer and blocking antibody studies suggested that loss of regulat

247 supernatants and its abrogation by anti-TrkB blocking antibody suggest that NaPB-induced astroglial n

248 e unaffected by pretreatment with a receptor-blocking antibody, suggesting that oxidative stress acti

249 atment of established tumours with ephrin-B2-blocking antibodies suppressed progression.

250 on of extracellular reelin with CR-50 reelin-blocking antibodies suppressed the increase in migratory

251 anism of the Fv and Fc portions of anti-TLR4 blocking antibodies that achieves increased potency on i

252 SLP, IL-33, and IL-25 and the development of blocking antibodies that target these epithelial cell-de

253 idney transplantation, treatment with a CD47-blocking antibody that improved function was associated

254 In the presence of a DAF-blocking antibody, the reduction in C3b deposition was r

255 as no corresponding increase in the specific blocking antibody titer.

256 Most subjects achieved HBGA-blocking antibody titers of >/=200.

257 xamined by comparing the effects of function-blocking antibodies to Ang2 or TNF, given individually o

258 Treatment with blocking antibodies to CD1a alleviated skin inflammation

259 porting system was exemplified by generating blocking antibodies to FGF4 and its receptor FGFR1beta,

260 T binding at this site in cells treated with blocking antibodies to IL-2 and the IL-2 receptor, sugge

261 these clones because it could be reduced if blocking antibodies to IL-4 were present.

262 AT3 phosphorylation, and myotube atrophy but blocking antibodies to IL-6 or OSM did not.

263 he use of radiation in combination with Ang2-blocking antibodies to improve the overall outcome of ca

264 Importantly, blocking antibodies to osteopontin mitigated but did not

265 neurons or slices after delivery of function-blocking antibodies to p75(NTR) or proNGF and in p75(NTR

266 study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels

267 Therapeutic use of blocking antibodies to PD-L1 or its receptor PD-1 has pr

268 Moreover, administration of EDA blocking antibodies to pregnant wild type mice induced i

269 We used monoclonal blocking antibodies to target a specific component in th

270 This priming effect was inhibited by blocking antibodies to TSLPR and ST2, respectively, and

271 ction by intraperitoneal administration of a blocking antibody to 6 week-old female NOD/ShiLtJ mice r

272 at the stage of virus attachment, and that a blocking antibody to beta2M inhibits echovirus infection

273 of multiple sclerosis (MS), we administered blocking antibody to CLEC12A that significantly ameliora

274 vo tumours with fractionated radiation and a blocking antibody to FGF2 prolongs tumour growth delay,

275 hermore, administration of glucagon receptor-blocking antibody to healthy individuals increased plasm

276 istered with a single dose of IFN-I receptor-blocking antibody to induce a short-term blockade of the

277 tion in AKI, we utilized a specific function-blocking antibody to inhibit alphavbeta5 in a rat model

278 Glycyrrhizin, a chelator of HMGB-1 and a blocking antibody to receptor for advanced glycation end

279 s essential residues that can be targeted by blocking antibody to reduce infection, and determines th

280 MF6 -/- cells, and the addition of the LAG-3-blocking antibody to the adoptive transfer protocol impr

281 re unaltered by the addition of a functional blocking antibody to the IGF-1R.

282 ergic transmission as well as a functionally blocking antibody toward the pan-neurotrophin receptor p

283 g down PD-1 expression or by using anti-PD-1 blocking antibodies, translated in vivo into better clea

284 malization of blood glucose levels with GCGR-blocking antibody unexpectedly doubled beta-cell mass re

285 The efficacy of the blocking antibodies was studied using cell culture, spin

286 A locally injected TNF blocking antibody was also able to inhibit neutrophil-de

287 Finally, using functional blocking antibodies, we identified E-cadherin as a major

288 Using receptor-blocking antibodies, we show that infection with the PDF

289 lar front migration was observed when Angpt2 blocking antibodies were administered to Tie1-deficient

290 rties to activate specific T cells or induce blocking antibodies were conserved.

291 Blocking antibodies were used to dissect the role of Tol

292 d functional, primarily Mal d 1-specific IgE-blocking antibodies, whereas rBet v 1 SLIT induced Bet v

293 We generated a new Met-blocking antibody which binds outside the ligand-binding

294 ptive transfer of Emicro-TCL1 CLL with PD-L1-blocking antibodies, which prevented CLL development and

295 f-of-concept that combining antiparasite MIF-blocking antibodies with current standard-of-care antibi

296 e results suggest that a combination of Ang2-blocking antibodies with radiation increases tumor growt

297 Combination of the anti-DCC function-blocking antibody with expression of DSCAM shRNA in prim

298 d CD8(+) T cells and administration of a PD1-blocking antibody with TEGVAX elicited complete regressi

299 Application of an IL-17A-blocking antibody within 3 hours after stroke induction

300 ty, we identify the most potent transmission-blocking antibody yet described against Pfs25; 2544.